As the nomenclature suggests, interleukin-1α (IL-1α) is the very first cytokine designated under the interleukin nomenclature system that now extends to interleukin-39. Interleukin-1 alpha (IL-1α) is a 20kD protein expressed on the surface of a variety of cells that mediates inflammation, where it plays a pivotal role in triggering and sustaining the inflammatory process. Due to its presence on platelets, keratinocytes of the skin, epithelial cells of the mucosal membranes throughout the body and cells of organs such as liver, lung and kidney, IL-1α is associated with pathological inflammatory responses, such as those observed in cancer, atherosclerosis, diabetes, dermatology and other diseases.
Targeting IL-1α with a neutralizing monoclonal antibody thus holds promise to treat many important disease processes. XBiotech’s anti-IL- 1α antibody therapeutic has been used in a number of human clinical studies, the results of which have been published in peer-reviewed journals and have further elucidated the benefit of IL-1α blockade in the treatment of inflammatory conditions. We believe this novel target holds promise as a breakthrough in the management of a significant portion of human disease.